Top Research Reports for Netflix, Medtronic, and AstraZeneca – July 15, 2021
Thursday July 15, 2021
Zacks Research Daily features the best research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Medtronic (MDT) and AstraZeneca (AZN). These research reports were handpicked from the roughly 70 reports released by our team of analysts today.
You can see all today’s research reports here >>>
Actions of Netflix have underperformed Zacks’ broadcast TV and radio industry over the past year (+ 3.2% vs. + 27.2%), but sentiment seems to have started to shift in recent times. The Zacks analyst believes that Netflix dominates the streaming space with its diverse content portfolio and heavy investments in the production and distribution of localized foreign language content.
User-friendly features like Downloads For You are key positives. The launch of low-cost mobile plans has the potential to expand Netflix’s subscriber base in Asia Pacific. A weak content roster and delayed production due to disruption caused by the coronavirus are expected to hurt Netflix’s prospects in the second quarter of 2021. Growing competition from Apple, Amazon, HBO Max, Disney + and Peacock is a major hurdle.
(You can read the full research report on Netflix here >>>)
Medtronic stocks have gained + 8.6% in the past six months against a gain of + 0.7% for Zacks’ medical products industry. The Zacks analyst believes that all of Medtronic’s major business groups have contributed to consistent revenue growth at CER, highlighting sustainability across groups and regions.
The results for the fourth quarter of fiscal 2021 reflect a strong recovery in the impact of the pandemic on elective procedures that the company experienced in April 2020. Gross and operating margins for the quarter also improved significantly. The company’s performance, however, was affected by deferred proceedings due to the pandemic.
(You can read the full research report on Medtronic here >>>)
Actions of AstraZeneca have gained + 14% in the last three months against the pharmaceutical industry’s gain of + 10% of Zacks Large Cap. The Zacks analyst believes that AstraZeneca’s new drugs, primarily the cancer drugs Lynparza, Tagrisso and Imfinzi, should continue to generate revenue.
It has a strong pipeline with a number of Phase III data readings scheduled for this year. Numerous external acquisitions and strategic collaborations are likely to strengthen the AstraZeneca pipeline. The company has a mixed record of earnings surprises in recent quarters.
(You can read the full research report on AstraZeneca here >>>)
Other notable reports we feature today include Amgen (AMGN), the company 3M (MMM) and reservation credits (BKNG).
Note: Sheraz Mian heads Zacks’ equity research department and is a renowned expert on aggregate earnings. He is frequently cited in print and electronic media and publishes the weekly Income trends and Income overview reports. If you would like to receive an email notification every time Sheraz publishes a new article, please click here >>>